Search results
Institute of Hematology and Blood Transfusion (Prague) to Present on Successful Use of Applied DNA’s...
The Kansas City Star· 3 days ago(NASDAQ:APDN) (Applied DNA), a leader in PCR-based DNA technologies, and the Institute of Hematology and Blood Transfusion (ÚHKT/IHBT) today announced that an abstract relating ...
Steward crisis adding to stresses on hospital care, as state scrambles to contain fallout - The...
The Boston Globe· 18 hours agoDr. Robbie Goldstein, commissioner of the state Department of Public Health, assured the council...
All About Harrison Butker's Parents, Harrison Butker Sr. and Elizabeth Butker
People Magazine· 18 hours agoMeet Harrison Butker's parents. Born in July 1995, the Kansas City Chiefs kicker is the son of...
Ryvu Therapeutics to present clinical and preclinical data on RVU120 at the 2024 European Hematology...
FOX 23 News Albany· 2 days agoUpdated data from the Phase I trial of RVU120 in patients with relapsed/refractory acute myeloid...
Klinikum Klagenfurt am Wörthersee is Live with SOPHiA GENETICS
FOX 5 San Diego· 6 hours agoSOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company and a leader in data-driven medicine, today announced that Klinikum Klagenfurt am Wörthersee, the third largest hospital in Austria ...
7 Low Magnesium Symptoms to Watch Out For, According to Doctors
Best Life· 5 days agoMagnesium is an essential mineral that's used in over 300 chemical reactions in the body, aiding in...
...Long-Term Follow-up of Rusfertide Phase 2 REVIVE Study Open Label Extension at the European ...
Morningstar· 2 days agoNEWARK, CA / ACCESSWIRE / May 14, 2024 / Protagonist Therapeutics, Inc. (NASDAQ:PTGX) ("Protagonist" or the "Company") today announced that additional data from the rusfertide Phase 2 REVIVE ...
Fighting lymphoma: Treatment options include alternatives to chemotherapy, expert explains
Medical Xpress· 21 hours agoChemotherapy is usually the first treatment doctors try to treat lymphoma, including the two most...
Dr. Daniel Geynisman Named New Editor-in-Chief for JNCCN--Journal of the National Comprehensive...
CBS 47 Fresno· 3 hours agoChief of the Genitourinary Division for Fox Chase Cancer Center, and Member of two NCCN Guidelines Panels to oversee high-impact oncology research journal. PLYMOUTH MEETING, Pa., May 16, 2024 ...
Promising Combination Therapy for Triple Negative Breast Cancer Treatment: A Milestone Collaboration...
Digital Journal· 1 day ago(NASDAQ: ABVC) ("Company"), a clinical-stage biopharmaceutical company developing therapeutic solutions in ophthalmology, CNS (central nervous systems), and Oncology/Hematology</ ...